|
|
Exchange: |
Nasdaq Small Cap |
Security
Type: |
Common |
Shares
Out: |
15,080,000 |
Market
Cap: |
22.77(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$1.42 - $2.3 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Cumberland Pharmaceuticals is a pharmaceutical company engaged on the acquisition, development and commercialization of prescription products. Co.'s portfolio of brands include: Acetadote® (acetylcysteine) injection, for the treatment of acetaminophen poisoning; Caldolor® (ibuprofen) injection, for the treatment of pain and fever; Kristalose® (lactulose) for the treatment of constipation; Omeclamox®-Pak, (omeprazole, clarithromycin, amoxicillin) for the treatment of Helicobacter pylori infection and related duodenal ulcer disease; and Vaprisol® (conivaptan) injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
27,346 |
Total Buy Value |
$0 |
$0 |
$0 |
$63,218 |
Total People Bought |
0 |
0 |
0 |
4 |
Total Buy Transactions |
0 |
0 |
0 |
444 |
Total Shares Sold |
0 |
0 |
0 |
0 |
Total Sell Value |
$0 |
$0 |
$0 |
$0 |
Total People Sold |
0 |
0 |
0 |
0 |
Total Sell Transactions |
0 |
0 |
0 |
0 |
End Date |
2024-02-18 |
2023-11-17 |
2023-05-19 |
2022-05-19 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Jones James |
Director |
|
2022-05-02 |
4 |
AB |
$2.45 |
$74 |
D/D |
30 |
20,713 |
|
-5% |
|
Young Caroline |
Director |
|
2022-05-02 |
4 |
AB |
$2.45 |
$49 |
D/D |
20 |
16,011 |
|
-5% |
|
Krogulski Kenneth |
Director |
|
2022-05-02 |
4 |
AB |
$2.45 |
$247 |
D/D |
101 |
185,311 |
|
-5% |
|
Herman James L |
VP and Chief Compliance Office |
|
2022-03-20 |
4 |
D |
$2.74 |
$3,507 |
D/D |
(1,280) |
40,721 |
|
- |
|
Kazimi A J |
Chairman and CEO |
|
2022-03-20 |
4 |
D |
$2.74 |
$101,942 |
D/D |
(37,205) |
5,753,358 |
|
- |
|
Cearnal Martin E |
Sr VP/Chief Commercial Officer |
|
2022-03-17 |
4 |
D |
$2.74 |
$41,100 |
D/D |
(15,000) |
163,473 |
|
- |
|
Krogulski Kenneth |
Director |
|
2022-03-16 |
4 |
A |
$2.59 |
$2,590 |
D/D |
1,000 |
184,141 |
|
- |
|
Kazimi A J |
Chairman and CEO |
|
2022-03-16 |
4 |
A |
$2.59 |
$51,800 |
D/D |
20,000 |
5,790,563 |
|
- |
|
Young Caroline |
Director |
|
2022-03-16 |
4 |
A |
$2.59 |
$2,590 |
D/D |
1,000 |
15,777 |
|
- |
|
Jones James |
Director |
|
2022-03-16 |
4 |
A |
$2.59 |
$2,590 |
D/D |
1,000 |
20,365 |
|
- |
|
Jacobs Joey A |
Director |
|
2022-03-16 |
4 |
A |
$2.59 |
$12,950 |
D/D |
5,000 |
103,415 |
|
- |
|
Galante Joseph C |
Director |
|
2022-03-16 |
4 |
A |
$2.59 |
$2,590 |
D/D |
1,000 |
45,061 |
|
- |
|
Hamm John M. |
Chief Financial Officer |
|
2022-03-16 |
4 |
A |
$2.59 |
$51,800 |
D/D |
20,000 |
26,800 |
|
- |
|
Jones James |
Director |
|
2021-12-20 |
4 |
AB |
$4.33 |
$281 |
D/D |
65 |
19,365 |
|
-47% |
|
Young Caroline |
Director |
|
2021-12-20 |
4 |
AB |
$4.33 |
$260 |
D/D |
60 |
14,777 |
|
-47% |
|
Krogulski Kenneth |
Director |
|
2021-12-20 |
4 |
AB |
$4.33 |
$1,195 |
D/D |
276 |
183,141 |
|
-47% |
|
Kazimi A J |
Chairman and CEO |
|
2021-12-20 |
4 |
AB |
$4.33 |
$260 |
D/D |
60 |
5,770,563 |
|
-47% |
|
Cearnal Martin E |
Sr VP/Chief Commercial Officer |
|
2021-12-20 |
4 |
AB |
$4.33 |
$1,360 |
D/D |
314 |
178,473 |
|
-47% |
|
Jones James |
Director |
|
2021-12-17 |
4 |
AB |
$4.17 |
$209 |
D/D |
50 |
19,300 |
|
-45% |
|
Young Caroline |
Director |
|
2021-12-17 |
4 |
AB |
$4.17 |
$209 |
D/D |
50 |
14,717 |
|
-45% |
|
Krogulski Kenneth |
Director |
|
2021-12-17 |
4 |
AB |
$4.17 |
$1,001 |
D/D |
240 |
182,865 |
|
-45% |
|
Kazimi A J |
Chairman and CEO |
|
2021-12-17 |
4 |
AB |
$4.17 |
$209 |
D/D |
50 |
5,770,503 |
|
-45% |
|
Cearnal Martin E |
Sr VP/Chief Commercial Officer |
|
2021-12-17 |
4 |
AB |
$4.17 |
$1,001 |
D/D |
240 |
178,159 |
|
-45% |
|
Jones James |
Director |
|
2021-12-16 |
4 |
AB |
$4.53 |
$227 |
D/D |
50 |
19,250 |
|
-42% |
|
Young Caroline |
Director |
|
2021-12-16 |
4 |
AB |
$4.53 |
$227 |
D/D |
50 |
14,667 |
|
-42% |
|
1400 Records found
|
|
Page 21 of 56 |
|
|